- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01092845
Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers
November 30, 2018 updated by: Pfizer
Double-Blind, Randomized, Multiple-Dose, Placebo-Controlled, 2-Way Crossover Study To Study Effects of PF-04457845 On Polysomnographic Endpoints In Healthy Volunteers
PF-04457845 has been shown to temporarily decrease the dream (REM) period of sleep in rats, which suggests that PF-04457845 is active in rat's brains.
This study is designed to see whether this is also the case in man.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10019
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects between the ages of 18 and 55 years
- Body Mass Index (BMI) between 17.5 and 30.5 kg/m2
- Total body weight >50 kg
Exclusion Criteria:
- History of any active sleep disorder
- History of any sleep or circadian rhythm sleep disorder including RLS, narcolepsy, sleep apnea, phase advance or delay syndromes within the past 5 years
- Currently on or planning to be involved in night or rotating shift work or traveling across more than four time zones in 14 days prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-04457845 followed by placebo
|
PF-04457845 4 mg tablet once daily / matched placebo
|
Experimental: Placebo followed by PF-04457845
|
PF-04457845 4 mg tablet once daily / matched placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of total sleep time spent in REM (ie, time spent in REM/total sleep time)
Time Frame: 3 days
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of total sleep time spent in Stage 1 sleep
Time Frame: 3 days
|
3 days
|
Percentage of total sleep time spent in Stage 2 sleep
Time Frame: 3 days
|
3 days
|
Percentage of total sleep time spent in Stage 3-4 sleep
Time Frame: 3 days
|
3 days
|
Total sleep time
Time Frame: 3 days
|
3 days
|
Latency to persistent sleep
Time Frame: 3 days
|
3 days
|
Minutes of REM sleep time
Time Frame: 3 days
|
3 days
|
Wake after sleep onset (sum of wake time during sleep and prior to final awakening) and wake time after sleep) (WASO)
Time Frame: 3 days
|
3 days
|
Number of arousals after sleep onset (NASO)
Time Frame: 3 days
|
3 days
|
Plasma concentrations of PF-04457845
Time Frame: 3 days
|
3 days
|
Plasma concentrations of fatty acid amides (N-arachidonyl ethanolamine (anandamide, AEA), palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and linoleoyl ethanolamine (LEA))
Time Frame: 3 days
|
3 days
|
Beta-band spectral power (qEEG) measured with eyes open and eyes closed while subjects are awake immediately before lights off for each PSG
Time Frame: 3 days
|
3 days
|
Beta-band spectral power (qEEG) measured with eyes open and eyes closed while subjects are awake immediately after lights on for each PSG
Time Frame: 3 days
|
3 days
|
Beta-band spectral power (qEEG) measured while subjects are asleep during the sleep onset period (SOP) and first 3 periods of NREM sleep
Time Frame: 3 days
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
March 23, 2010
First Submitted That Met QC Criteria
March 23, 2010
First Posted (Estimate)
March 25, 2010
Study Record Updates
Last Update Posted (Actual)
December 4, 2018
Last Update Submitted That Met QC Criteria
November 30, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- B0541010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on PF-04457845 / matched placebo
-
PfizerTerminatedSleep | Healthy VolunteersUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedCannabis DependenceUnited States
-
Yale UniversityCompleted
-
PfizerTerminatedPost-Traumatic Stress DisorderUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; Johns Hopkins University and other collaboratorsCompletedCannabis Use DisorderUnited States
-
Yale UniversityTourette Association of AmericaTerminated
-
PfizerCompleted
-
PfizerCompletedChronic Pain | Acute PainSingapore
-
PfizerTerminatedUlcerative ColitisUnited States, Australia, Italy, Korea, Republic of, Belgium, Israel, Turkey, Saudi Arabia, Germany, Serbia
-
GlaxoSmithKlineCompletedMuscular DystrophiesGermany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom